Development of a composite endpoint for randomized controlled trials in liver surgery

British Journal of Surgery

Volumn 98, Issue 8, 2011, Pages 1138-1145

  Van Den Broek, M A J ^a   Van Dam, R M ^a   Van Breukelen, G J P ^b   Bemelmans, M H ^a   Oussoultzoglou, E ^c   Pessaux, P ^c   Dejong, C H C ^a,b   Freemantle, N ^d   Olde Damink, S W M ^a,b,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BIOASSAY; CONSENSUS; FEMALE; HUMAN; LIVER DISEASE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; CONSENSUS; ENDPOINT DETERMINATION; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959948958     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7503     Document Type: Article

References (20)

1. Kaido T,. Analysis of randomized controlled trials on hepatopancreatic surgery. Dig Dis Sci 2006; 51: 1761-1766.
2. van den Broek MA, van Dam RM, Malagõ M, Dejong CH, van Breukelen GJ, Olde Damink SW,. Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint. Br J Surg 2009; 96: 1005-1014.
3. Freemantle N,. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ 2001; 322: 989-991. (Pubitemid 32374693)
4. Freemantle N,. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 2005; 331: 836-838. (Pubitemid 41442369)
5. Washburn K,. Endpoints in trials for clinical liver transplantation. Curr Opin Organ Transplant 2008; 13: 252-256.
6. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C,. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289: 2554-2559. (Pubitemid 37430157)
7. Ferreira-González I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, et al., Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007; 60: 651-657. (Pubitemid 46901008)
8. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al., Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007; 334: 786.
9. Dindo D, Demartines N, Clavien PA,. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213. (Pubitemid 38963009)
10. Neaton JD, Gray G, Zuckerman BD, Konstam MA,. Key issues in end point selection for heart failure trials: composite end points. J Card Fail 2005; 11: 567-575. (Pubitemid 41463726)
11. Califf RM, Harrelson-Woodlief L, Topol EJ,. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation 1990; 82: 1847-1853. (Pubitemid 20367987)
12. Lim E, Brown A, Helmy A, Mussa S, Altman DG,. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med 2008; 149: 612-617.
13. Bethel MA, Holman R, Haffner SM, Califf RM, Huntsman-Labed A, Hua TA, et al., Determining the most appropriate components for a composite clinical trial outcome. Am Heart J 2008; 156: 633-640.
14. Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, et al., Validity of composite end points in clinical trials. BMJ 2005; 330: 594-596. (Pubitemid 40380357)
15. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al., The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-196.
16. Neuhäuser M,. How to deal with multiple endpoints in clinical trials. Fundam Clin Pharmacol 2006; 20: 515-523. (Pubitemid 44760171)
17. Martin RC II, Brennan MF, Jaques DP,. Quality of complication reporting in the surgical literature. Ann Surg 2002; 235: 803-813. (Pubitemid 34547298)
18. Gluud C,. The culture of designing hepato-biliary randomised trials. J Hepatol 2006; 44: 607-615. (Pubitemid 43227886)
19. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, et al., No surgical innovation without evaluation: the IDEAL recommendations. Lancet 2009; 374: 1105-1112.
20. Pitt HA, Kilbane M, Strasberg SM, Pawlik TM, Dixon E, Zyromski NJ, et al., ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford) 2009; 11: 405-413.